{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:55:24Z","timestamp":1793058924093,"version":"4.5.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The B-cell lymphoma 2 inhibitor venetoclax has shown promise for treating acute myeloid leukemia (AML). However, identifying patients likely to respond remains a challenge, especially for those with relapsed\/refractory (R\/R) disease. We evaluated the utility of ex\u00a0vivo venetoclax sensitivity testing to predict treatment responses to venetoclax-azacitidine in a prospective, multicenter, phase 2 trial. The trial recruited 104 participants with previously untreated (n\u00a0=\u00a048), R\/R (n\u00a0=\u00a039), or previously treated secondary AML (sAML) (n\u00a0=\u00a017). The primary end point was complete remission or complete remission with incomplete hematologic recovery (CR\/CRi) rate in ex\u00a0vivo sensitive trial participants during the first 3 therapy cycles. The key secondary end points included the correlations between ex\u00a0vivo drug sensitivity, responses, and survival. Venetoclax sensitivity was successfully assessed in 102 of 104 participants, with results available within a median of 3 days from sampling. In previously untreated AML, ex\u00a0vivo sensitivity corresponded to an 85% (34\/40) CR\/CRi rate, with a median overall survival (OS) of 28.7 months, compared with 5.5 months for ex\u00a0vivo resistant patients (P\u00a0=\u00a0.002). For R\/R\/sAML, ex\u00a0vivo sensitivity resulted in a 62% CR\/CRi rate (21\/34) and median OS of 9.7 vs 3.3 months for ex\u00a0vivo resistant patients (P\u00a0&amp;lt; .001). In univariate and multivariate analysis, ex\u00a0vivo venetoclax sensitivity was the strongest predictor for a favorable treatment response and survival. This trial demonstrates the feasibility of integrating ex\u00a0vivo drug testing into clinical practice to identify patients with AML, particularly in the R\/R setting, who benefit from venetoclax. This trial was registered at www.clinicaltrials.gov as\u00a0#NCT04267081.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024024968","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T20:56:41Z","timestamp":1727902601000},"page":"409-421","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":37,"title":["Ex\u00a0vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1649-8993","authenticated-orcid":false,"given":"Sari","family":"Kyt\u00f6l\u00e4","sequence":"first","affiliation":[{"name":"1Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9764-3477","authenticated-orcid":false,"given":"Ida","family":"V\u00e4nttinen","sequence":"additional","affiliation":[{"name":"2Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4825-8599","authenticated-orcid":false,"given":"Tanja","family":"Ruokoranta","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Partanen","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Kuopio University Hospital, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annasofia","family":"Holopainen","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Kuopio University Hospital, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7701-0328","authenticated-orcid":false,"given":"Joseph","family":"Saad","sequence":"additional","affiliation":[{"name":"2Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milla E. L.","family":"Kuusisto","sequence":"additional","affiliation":[{"name":"4Department of Hematology, University of Oulu, Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirpa","family":"Koskela","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine, Tampere University Hospital, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"R\u00e4ty","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5844-1632","authenticated-orcid":false,"given":"Maija","family":"It\u00e4l\u00e4-Remes","sequence":"additional","affiliation":[{"name":"6Department of Clinical Hematology and Stem Cell Transplantations, Turku University Hospital, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imre","family":"V\u00e4strik","sequence":"additional","affiliation":[{"name":"2Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Suvela","sequence":"additional","affiliation":[{"name":"2Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alun","family":"Parsons","sequence":"additional","affiliation":[{"name":"2Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4112-5902","authenticated-orcid":false,"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"Wennerberg","sequence":"additional","affiliation":[{"name":"7Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4324-8706","authenticated-orcid":false,"given":"Caroline A.","family":"Heckman","sequence":"additional","affiliation":[{"name":"2Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4586-8378","authenticated-orcid":false,"given":"Tero","family":"Jalkanen","sequence":"additional","affiliation":[{"name":"8EstiMates Ltd, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppo","family":"Huttunen","sequence":"additional","affiliation":[{"name":"8EstiMates Ltd, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Ettala","sequence":"additional","affiliation":[{"name":"6Department of Clinical Hematology and Stem Cell Transplantations, Turku University Hospital, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Rimpil\u00e4inen","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine, Tampere University Hospital, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Siitonen","sequence":"additional","affiliation":[{"name":"4Department of Hematology, University of Oulu, Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja","family":"Py\u00f6r\u00e4l\u00e4","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Kuopio University Hospital, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-0408","authenticated-orcid":false,"given":"Heikki","family":"Kuusanm\u00e4ki","sequence":"additional","affiliation":[{"name":"2Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland"},{"name":"9Foundation for the Finnish Cancer Institute, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6353-0664","authenticated-orcid":false,"given":"Mika","family":"Kontro","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland"},{"name":"9Foundation for the Finnish Cancer Institute, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2025012316204433800_bib1","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1158\/2159-8290.CD-13-0832","article-title":"Personalized therapy for acute myeloid leukemia","volume":"3","author":"Hourigan","year":"2013","journal-title":"Cancer Discov"},{"issue":"7","key":"2025012316204433800_bib2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2025012316204433800_bib3","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-Day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"11","key":"2025012316204433800_bib4","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2025012316204433800_bib5","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"2025012316204433800_bib6","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2025012316204433800_bib7","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.27231","article-title":"Clinical outcomes of hypomethylating agents plus venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: real-world data from eight US academic centers","volume":"99","author":"Abaza","year":"2024","journal-title":"Am J Hematol"},{"key":"2025012316204433800_bib8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","author":"D\u00f6hner","year":"12 \u00a02024","journal-title":"Blood J"},{"issue":"4","key":"2025012316204433800_bib9","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv"},{"issue":"12","key":"2025012316204433800_bib10","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat Cancer"},{"issue":"9","key":"2025012316204433800_bib11","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","article-title":"A\u00a0novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy","volume":"13","author":"Pei","year":"2023","journal-title":"Cancer Discov"},{"issue":"4","key":"2025012316204433800_bib12","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"14","key":"2025012316204433800_bib13","doi-asserted-by":"crossref","first-page":"e7378","DOI":"10.1002\/cam4.7378","article-title":"Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents","volume":"13","author":"Jin","year":"2024","journal-title":"Cancer Med"},{"issue":"6","key":"2025012316204433800_bib14","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov"},{"issue":"2","key":"2025012316204433800_bib15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","article-title":"Implementing a functional precision medicine tumor board for acute myeloid leukemia","volume":"12","author":"Malani","year":"2022","journal-title":"Cancer Discov"},{"issue":"8","key":"2025012316204433800_bib16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41419-019-1801-0","article-title":"Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling","volume":"10","author":"Seyfried","year":"2019","journal-title":"Cell Death Dis"},{"issue":"10","key":"2025012316204433800_bib17","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"2","key":"2025012316204433800_bib18","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","article-title":"Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders","volume":"12","author":"Kornauth","year":"2022","journal-title":"Cancer Discov"},{"issue":"12","key":"2025012316204433800_bib19","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/s43018-023-00645-5","article-title":"Ex\u00a0vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial","volume":"4","author":"Liebers","year":"2023","journal-title":"Nat Cancer"},{"issue":"20","key":"2025012316204433800_bib20","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2025012316204433800_bib21","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2025012316204433800_bib22","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3324\/haematol.2022.281692","article-title":"Ex\u00a0vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia","volume":"108","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"2025012316204433800_bib23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2025012316204433800_bib24","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2025012316204433800_bib25","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025012316204433800_bib26","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci Rep"},{"issue":"3","key":"2025012316204433800_bib27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"2025012316204433800_bib28","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/ajh.25567","article-title":"Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"94","author":"Aldoss","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"2025012316204433800_bib29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/cancers14010022","article-title":"Venetoclax in relapsed\/refractory acute myeloid leukemia: are supporting evidences enough?","volume":"14","author":"Brancati","year":"2021","journal-title":"Cancers"},{"issue":"14","key":"2025012316204433800_bib30","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.3390\/cancers14143456","article-title":"Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for venetoclax-based combination therapies","volume":"14","author":"Griffioen","year":"2022","journal-title":"Cancers"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/4\/409\/2352000\/blood_bld-2024-024968-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/4\/409\/2352000\/blood_bld-2024-024968-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T16:21:01Z","timestamp":1737649261000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/4\/409\/518024\/Ex-vivo-venetoclax-sensitivity-predicts-clinical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,1,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024968","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}